The most-read coverage of the latest updates in acute myeloid leukemia (AML) for 2025 focused on the evolution of targeted therapies, the promise of off-the-shelf chimeric antigen receptor (CAR) ...
AML (acute myeloid leukemia) remains a deadly, hard-to-treat disease. Agios has AG-221 in a Phase 3 trial for AML. ImmunoGen has IMGN779 in a Phase 1 trial for AML. FDA approval would likely lead to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback